{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:35:58Z","timestamp":1794958558314,"version":"4.9.1"},"reference-count":96,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.eururo.2023.04.010","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T08:18:57Z","timestamp":1683879537000},"page":"289-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":240,"title":["European Association of Urology Guidelines on Testicular Cancer: 2023 Update"],"prefix":"10.1016","volume":"84","author":[{"given":"Anna","family":"Patrikidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Berney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"de Angst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Di Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fankhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gravina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Gremmels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Janisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Le\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Nicolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Oing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torgrim","family":"Tandstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.04.010_b0005","doi-asserted-by":"crossref","first-page":"e12390","DOI":"10.1097\/MD.0000000000012390","article-title":"Recent global trends in testicular cancer incidence and mortality","volume":"97","author":"Park","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.eururo.2023.04.010_b0010","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00345-014-1361-y","article-title":"Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009","volume":"33","author":"Nigam","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0015","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.eururo.2019.07.002","article-title":"International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries","volume":"76","author":"Gurney","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0020","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2015.07.044","article-title":"Guidelines on testicular cancer: 2015 update","volume":"68","author":"Albers","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0025","unstructured":"Howick J. Levels of evidence. Oxford, UK: Centre for Evidence- based Medicine; 2009. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009."},{"key":"10.1016\/j.eururo.2023.04.010_b0030","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/JU.0000000000000594","article-title":"Performance characteristics of clinical staging modalities for early stage testicular germ cell tumors: a systematic review","volume":"203","author":"Pierorazio","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0035","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.2015.62.7000","article-title":"Brain metastases in patients with germ cell tumors: prognostic factors and treatment options\u2014an analysis from the Global Germ Cell Cancer Group","volume":"34","author":"Feldman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0040","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.20.03296","article-title":"Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium","volume":"39","author":"Gillessen","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0045","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrurol.2010.166","article-title":"Serum tumor markers in the evaluation of male germ cell tumors","volume":"7","author":"Barlow","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0050","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.bjc.6602682","article-title":"A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial","volume":"93","author":"Mead","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2023.04.010_b0055","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.eururo.2021.06.006","article-title":"Circulating microRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review","volume":"80","author":"Le\u00e3o","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.euo.2020.11.004","article-title":"Utility of serum miR-371a-3p in predicting relapse on surveillance in patients with clinical stage I testicular germ cell cancer","volume":"4","author":"Lobo","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0065","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2020.02.023","article-title":"Testis-sparing surgery and scrotal violation for testicular masses suspicious for malignancy: a systematic review and meta-analysis","volume":"38","author":"Patel","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0070","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<815::AID-IJC21>3.0.CO;2-Z","article-title":"Carcinoma In situ of the testis: review of biological and clinical features","volume":"83","author":"Dieckmann","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2023.04.010_b0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.eururo.2006.05.051","article-title":"Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy","volume":"51","author":"Dieckmann","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0080","doi-asserted-by":"crossref","first-page":"605.e19","DOI":"10.1016\/j.urolonc.2020.03.012","article-title":"Partial orchiectomy: the Princess Margaret Cancer Centre experience","volume":"38","author":"Nason","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0085","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.euf.2020.06.019","article-title":"The role of frozen section examination during inguinal exploration in men with inconclusive testicular tumors: a systematic review and meta-analysis","volume":"7","author":"Fankhauser","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.04.010_b0090","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/suro.2002.36980","article-title":"Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated?","volume":"20","author":"Heidenreich","year":"2002","journal-title":"Semin Urol Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0095","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0022-5347(17)38967-X","article-title":"Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidism","volume":"142","author":"Giwercman","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0100","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.clgc.2016.07.006","article-title":"Preorchiectomy Leydig cell dysfunction in patients with testicular cancer","volume":"15","author":"Bandak","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2023.04.010_b0105","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2164\/jandrol.112.016592","article-title":"The semen quality of 1158 men with testicular cancer at the time of cryopreservation: results of the French National CECOS Network","volume":"33","author":"Rives","year":"2012","journal-title":"J Androl"},{"key":"10.1016\/j.eururo.2023.04.010_b0110","series-title":"TNM classification of malignant tumours","year":"2016"},{"key":"10.1016\/j.eururo.2023.04.010_b0115","series-title":"AJCC cancer staging manual","year":"2017"},{"key":"10.1016\/j.eururo.2023.04.010_b0120","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2002.01.038","article-title":"Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis","volume":"20","author":"Warde","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0125","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.eururo.2017.09.025","article-title":"Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage I seminoma testis patients under surveillance: a systematic review by the Testicular Cancer Guidelines Panel","volume":"73","author":"Boormans","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0130","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1097\/PAS.0000000000001049","article-title":"Intraoperative consultation and macroscopic handling: the International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference recommendations","volume":"42","author":"Verrill","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2023.04.010_b0135","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/annonc\/mdi175","article-title":"Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review","volume":"16","author":"Hoei-Hansen","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0140","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1200\/JCO.2002.20.6.1537","article-title":"Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis","volume":"20","author":"Petersen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0145","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/sj.bjc.6600771","article-title":"Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group","volume":"88","author":"Classen","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2023.04.010_b0150","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/JU.0000000000000318","article-title":"Diagnosis and treatment of early stage testicular cancer: AUA guideline","volume":"202","author":"Stephenson","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0155","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/annonc\/mds628","article-title":"Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: a survey of the German Testicular Cancer Study Group","volume":"24","author":"Dieckmann","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0160","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2002.07.062","article-title":"Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis","volume":"20","author":"Bokemeyer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0165","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","article-title":"Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance","volume":"33","author":"Kollmannsberger","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0170","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.critrevonc.2007.04.014","article-title":"A comprehensive systematic review of testicular germ cell tumor surveillance","volume":"64","author":"Groll","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eururo.2023.04.010_b0175","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2016.07.013","article-title":"Conditional risk of relapse in surveillance for clinical stage I testicular cancer","volume":"71","author":"Nayan","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0180","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2010.30.1044","article-title":"Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group","volume":"29","author":"Tandstad","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0185","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.clon.2009.08.006","article-title":"Management of stage I seminomatous testicular cancer: a systematic review","volume":"22","author":"Chung","year":"2010","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0190","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.euf.2020.06.012","article-title":"Cost-effectiveness analysis of non\u2013risk-adapted active surveillance for postorchiectomy management of clinical stage I seminoma","volume":"7","author":"Huang","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.04.010_b0195","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1200\/JCO.2009.26.4655","article-title":"Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19\/EORTC 30982 study (ISRCTN27163214)","volume":"29","author":"Oliver","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0200","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/annonc\/mdw164","article-title":"Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)","volume":"27","author":"Tandstad","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0205","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0022-5347(17)36046-9","article-title":"Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation","volume":"149","author":"Donohue","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0210","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.eururo.2010.08.032","article-title":"Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence","volume":"58","author":"Nicolai","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0215","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.juro.2017.09.088","article-title":"Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: safety and efficacy analyses at a high volume center","volume":"199","author":"Nicolai","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0220","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/JU.0000000000001301","article-title":"Robotic assisted retroperitoneal lymph node dissection for small volume metastatic testicular cancer","volume":"204","author":"Hiester","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0225","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1093\/annonc\/mdu375","article-title":"One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group","volume":"25","author":"Tandstad","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0230","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1200\/JCO.2008.18.8953","article-title":"Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program","volume":"27","author":"Tandstad","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0235","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.eururo.2004.03.022","article-title":"Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and\/or vascular invasion","volume":"46","author":"Chevreau","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0240","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO.2003.06.065","article-title":"Radiotherapy for stages IIA\/B testicular seminoma: final report of a prospective multicenter clinical trial","volume":"21","author":"Classen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0245","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2004.01.020","article-title":"Stage II testicular seminoma: patterns of recurrence and outcome of treatment","volume":"45","author":"Chung","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0250","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/annonc\/mdm062","article-title":"Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)","volume":"18","author":"Culine","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0255","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdu447","article-title":"Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes","volume":"26","author":"Giannatempo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0260","doi-asserted-by":"crossref","unstructured":"Neuenschwander A, Lonati C, Antonelli L, et al. Treatment outcomes for men with clinical stage II nonseminomatous germ cell tumours treated with primary retroperitoneal lymph node dissection: a systematic review. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2022.11.003.","DOI":"10.1016\/j.euf.2022.11.003"},{"key":"10.1016\/j.eururo.2023.04.010_b0265","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6602020","article-title":"Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials","volume":"91","author":"Bokemeyer","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2023.04.010_b0270","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1200\/JCO.1997.15.5.1837","article-title":"Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group","volume":"15","author":"de Wit","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0275","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/bjc.1998.587","article-title":"Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group","volume":"78","author":"de Wit","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2023.04.010_b0280","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.1998.16.4.1287","article-title":"Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study","volume":"16","author":"Nichols","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0285","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2005.05.4528","article-title":"Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors","volume":"25","author":"Motzer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0290","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1200\/JCO.2004.04.008","article-title":"Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors","volume":"22","author":"Fizazi","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0295","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/S1470-2045(14)70490-5","article-title":"Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0300","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/annonc\/mdq575","volume":"22","author":"Daugaard","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0305","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00345-022-04009-z","article-title":"How to classify, diagnose, treat and follow-up extragonadal germ cell tumors? A systematic review of available evidence","volume":"40","author":"Winter","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0310","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.euf.2020.09.017","article-title":"A risk-benefit analysis of prophylactic anticoagulation for patients with metastatic germ cell tumours undergoing first-line chemotherapy","volume":"7","author":"Fankhauser","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.04.010_b0315","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.euros.2021.07.007","article-title":"Thromboembolic events during treatment with cisplatin-based chemotherapy in metastatic testicular germ-cell cancer 2000\u20132014: a population-based cohort study","volume":"32","author":"Haugnes","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2023.04.010_b0320","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0959-8049(00)00137-4","article-title":"The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients","volume":"36","author":"Andr\u00e9","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2023.04.010_b0325","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000282874","article-title":"Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection","volume":"57","author":"Hofmockel","year":"1996","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2023.04.010_b0330","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.1996.14.2.454","article-title":"Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center","volume":"14","author":"Puc","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0335","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2004.07.188","article-title":"2\u201318Fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial","volume":"22","author":"Santis","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0340","doi-asserted-by":"crossref","first-page":"5930","DOI":"10.1200\/JCO.2008.17.1157","article-title":"[18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German Multicenter Positron Emission Tomography Study Group","volume":"26","author":"Oechsle","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0345","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1097\/01.ju.0000060121.33899.4b","article-title":"Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?","volume":"169","author":"Mosharafa","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0350","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<856::AID-IJC31>3.0.CO;2-L","article-title":"Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer","volume":"83","author":"Steyerberg","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2023.04.010_b0355","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/suro.2002.36977","article-title":"The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies","volume":"20","author":"Sheinfeld","year":"2002","journal-title":"Semin Urol Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0360","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/cncr.10440","article-title":"Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses","volume":"94","author":"Hendry","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2023.04.010_b0365","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0959-8049(96)00517-5","article-title":"Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours","volume":"33","author":"Hartmann","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2023.04.010_b0370","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1200\/JCO.2003.03.184","article-title":"Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses","volume":"21","author":"Oldenburg","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0375","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.euo.2020.08.007","article-title":"Long-term surveillance of patients with complete response following chemotherapy for metastatic nonseminomatous germ cell tumor","volume":"4","author":"Nason","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0380","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/JCO.2009.23.0714","article-title":"Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission?","volume":"28","author":"Ehrlich","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0385","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.2004.07.124","article-title":"Residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer","volume":"22","author":"Rick","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0390","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.eururo.2008.09.027","article-title":"Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection","volume":"55","author":"Heidenreich","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0395","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(01)64506-3","article-title":"Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group","volume":"158","author":"Steyerberg","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0400","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jtcvs.2008.09.032","article-title":"Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis","volume":"137","author":"Besse","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.eururo.2023.04.010_b0405","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/annonc\/mdu099","article-title":"Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial","volume":"25","author":"Fizazi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0410","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2009.26.8128","article-title":"Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy","volume":"28","author":"Group IPFS","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0415","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1200\/JCO.1995.13.5.1170","article-title":"Late relapse of testicular cancer","volume":"13","author":"Baniel","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0420","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/sj.bjc.6603014","article-title":"Late recurrences of germ cell malignancies: a population-based experience over three decades","volume":"94","author":"Oldenburg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2023.04.010_b0425","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00345-004-0397-9","article-title":"Late relapse of testicular cancer","volume":"22","author":"Lipphardt","year":"2004","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.04.010_b0430","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/jnci\/djq216","article-title":"Testicular cancer survivorship: research strategies and recommendations","volume":"102","author":"Travis","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2023.04.010_b0435","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1200\/JCO.2012.43.4431","article-title":"Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up","volume":"30","author":"Haugnes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0440","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(18)30903-3","article-title":"Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study","volume":"20","author":"Bright","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0445","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.19.01180","article-title":"Cardiovascular risk factors and disease after male germ cell cancer","volume":"38","author":"Lauritsen","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0450","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2017.77.0735","article-title":"Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study","volume":"36","author":"Kerns","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0455","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2003.04.173","article-title":"Cardiovascular disease as a long-term complication of treatment for testicular cancer","volume":"21","author":"Huddart","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0460","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/andr.12354","article-title":"Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome","volume":"5","author":"Bogefors","year":"2017","journal-title":"Andrology"},{"key":"10.1016\/j.eururo.2023.04.010_b0465","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2003.02.075","article-title":"Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group\/Medical Research Council Testicular Cancer Study Group (30941\/TE20)","volume":"21","author":"Foss\u00e5","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.04.010_b0470","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/pon.4596","article-title":"A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors","volume":"27","author":"Smith","year":"2018","journal-title":"Psycho-oncology"},{"key":"10.1016\/j.eururo.2023.04.010_b0475","article-title":"Adverse health outcomes among US testicular cancer survivors after cisplatin-based chemotherapy vs surgical management","volume":"4","author":"Agrawal","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.eururo.2023.04.010_b0480","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.20.03292","article-title":"Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-Update Consortium","volume":"39","author":"Beyer","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382302732X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382302732X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:14:05Z","timestamp":1759583645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382302732X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S030228382302732X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.04.010","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Association of Urology Guidelines on Testicular Cancer: 2023 Update","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}